Talimogene laherparepvec in combination with cisplatin + radiotherapy in patients receiving first-line therapy for the treatment of locally advanced head and neck cancer
Phase of Trial: Phase I/II
Latest Information Update: 02 Aug 2010
At a glance
- Drugs Talimogene laherparepvec (Primary)
- Indications Head and neck cancer
- Focus Adverse reactions
- Sponsors BioVex
- 02 Aug 2010 Results published today in Clinical Cancer Research, as reported in a BioVex media release.
- 02 Aug 2010 Status changed from active, no longer recruiting to completed, as reported in a BioVex media release.
- 02 Jun 2009 Results were presented at ASCO 2009, and in a BioVex media release.